Zobrazeno 1 - 10
of 291
pro vyhledávání: '"Juris J, Meier"'
Publikováno v:
Diabetes & Metabolism Journal, Vol 47, Iss 1, Pp 140-146 (2023)
In clinical practice, the distinction between type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) can be challenging, leaving patients with “ambiguous” diabetes type. Insulin-treated patients (n=115) previously diagnosed with T2DM
Externí odkaz:
https://doaj.org/article/29e7a9aed8e04adcbfabb38109f34c39
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-9 (2022)
Abstract Cardiovascular outcomes trials (CVOTs) with novel drugs to treat type 2 diabetes have uniformly chosen the composite “major adverse cardiovascular events (MACE)” as their primary endpoint, but they also report hazard ratios for individua
Externí odkaz:
https://doaj.org/article/7f7efbf9353e4f0f80056a38b2d032c7
Autor:
Frank Petrak, Stephan Herpertz, Julia Hirsch, Bonnie Röhrig, Iris Donati-Hirsch, Georg Juckel, Juris J. Meier, Sören Gatermann
Publikováno v:
BMC Microbiology, Vol 22, Iss 1, Pp 1-11 (2022)
Abstract Background Individuals with type 1 diabetes and those with depression show differences in the composition of the gut microbiome from that of healthy people. However, these differences have not yet been studied in patients with both diseases.
Externí odkaz:
https://doaj.org/article/a0015c73bbe743b0beb5135f1a94cbbc
Autor:
Juris J. Meier
Publikováno v:
Сахарный диабет, Vol 22, Iss 5, Pp 461-466 (2019)
The ever-increasing burden of type 2 diabetes mellitus (T2DM) worldwide, has led to the emergence of several antidiabetes drugs with different modes of action. Incretin hormones and their effect on glucose metabolism and pathogenesis of T2DM has been
Externí odkaz:
https://doaj.org/article/3f80af6f0ce043bc92ebdb42b6a1472a
Publikováno v:
Frontiers in Endocrinology, Vol 12 (2021)
Externí odkaz:
https://doaj.org/article/e83b467076404b0d9b06cdb3941d3d5b
Autor:
Juris J. Meier
Publikováno v:
Frontiers in Endocrinology, Vol 12 (2021)
Despite the benefits of early and effective glycemic control in the management of type 2 diabetes (T2D), achieving glycated hemoglobin (HbA1c) targets is challenging in some patients. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) provide effec
Externí odkaz:
https://doaj.org/article/19a43517fb234f7698ccc2c0f0582ad9
Autor:
Daniel R Quast, Georgios C Boronikolos, Bjoern A Menge, Thomas GK Breuer, Nina Schenker, Juris J Meier
Publikováno v:
Experimental and Clinical Endocrinology & Diabetes. 131:299-306
Aims Gastrointestinal disorders, including constipation and fecal incontinence, are common in type 2 diabetes mellitus (T2DM) and may derive from diabetic autonomic neuropathy, severe intestinal bacterial overgrowth, or a dysfunctional anorectal sphi
Autor:
Vanita R. Aroda, Umut Erhan, Peter Jelnes, Juris J. Meier, Morten Tind Abildlund, Richard Pratley, Tina Vilsbøll, Mansoor Husain
Publikováno v:
Diabetes, Obesity and Metabolism. 25:1385-1397
Publikováno v:
Molecular Metabolism, Vol 46, Iss , Pp 101102- (2021)
Background: GLP-1 receptor agonists (GLP-1 RAs) with exenatide b.i.d. first approved to treat type 2 diabetes in 2005 have been further developed to yield effective compounds/preparations that have overcome the original problem of rapid elimination (
Externí odkaz:
https://doaj.org/article/6a8b1c7fd03844fc9ad3a6585f22a6ea
Autor:
Vanita R. Aroda, Robert Bauer, Erik Christiansen, Martin Haluzík, Klaus Kallenbach, Eduard Montanya, Julio Rosenstock, Juris J. Meier
Publikováno v:
Diabetes, Obesity and Metabolism. 24:1338-1350
To evaluate the efficacy and safety of oral semaglutide versus comparators by patient characteristic subgroups in patients with type 2 diabetes.Change from baseline in glycated haemoglobin (HbA1c) and body weight, and achievement of HbA1c 7.0% with o